<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cardiovasc Disord</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cardiovasc Disord</journal-id><journal-title-group><journal-title>BMC Cardiovascular Disorders</journal-title></journal-title-group><issn pub-type="epub">1471-2261</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786336</article-id><article-id pub-id-type="publisher-id">4496</article-id><article-id pub-id-type="doi">10.1186/s12872-025-04496-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Extracellular volume fraction and native T1 mapping in diabetic cardiomyopathy: a comprehensive meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Marey</surname><given-names>Ahmed</given-names></name><address><email>ahmed.ahmed1797@alexmed.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alabdullah</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghorab</surname><given-names>Hossam</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Fatima</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Abdulla</surname><given-names>Jawdat</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Narang</surname><given-names>Akhil</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Umair</surname><given-names>Muhammad</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mzz1w90</institution-id><institution-id institution-id-type="GRID">grid.7155.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2260 6941</institution-id><institution>Alexandria University Faculty of Medicine, </institution></institution-wrap>Champollion street&#x0060c;, Al Mesallah Sharq, Al Attarin, Alexandria Governorate, Alexandria, 5372066 Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.517650.0</institution-id><institution>Department of Surgery, </institution><institution>Cleveland Clinic Abu Dhabi, </institution></institution-wrap>Abu Dhabi, United Arab Emirates </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vhsg885</institution-id><institution-id institution-id-type="GRID">grid.413620.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0608 9675</institution-id><institution>CMH Lahore Medical College, </institution></institution-wrap>Lahore, Pakistan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00edrn755</institution-id><institution-id institution-id-type="GRID">grid.411905.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 8202</institution-id><institution>Department of Cardiology, </institution><institution>Amager and Hvidovre Hospital, </institution></institution-wrap>Hvidovre, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/000e0be47</institution-id><institution-id institution-id-type="GRID">grid.16753.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2299 3507</institution-id><institution>Department of Cardiology, </institution><institution>Northwestern University, </institution></institution-wrap>Evanston, IL USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cb1k848</institution-id><institution-id institution-id-type="GRID">grid.411935.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2192 2723</institution-id><institution>Russell H. Morgan Department of Radiology and Radiological Sciences, </institution><institution>The Johns Hopkins Hospital, </institution></institution-wrap>Baltimore, MD USA </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>70</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Type 2 diabetes mellitus (T2DM) is associated with myocardial fibrosis (MF), a major contributor to adverse cardiovascular outcomes. Cardiovascular magnetic resonance (CMR), specifically extracellular volume fraction (ECV) and native T1 mapping, offers a non-invasive approach to quantify MF. This study aims to evaluate the utility of ECV and native T1 mapping as biomarkers for cardiac fibrosis and to assess their relationship with diabetes severity, measured by hemoglobin A1C (HbA1C), in patients with T2DM.</p></sec><sec><title>Methods</title><p id="Par2">A systematic review and meta-analysis were conducted following PRISMA guidelines. Comprehensive searches identified 19 eligible studies comprising 4,117 participants. Weighted mean differences (WMDs) were calculated for ECV and native T1 values between diabetic and non-diabetic groups. Meta-regression assessed the correlation between ECV and HbA1C. Sensitivity and subgroup analyses were performed to explore heterogeneity.</p></sec><sec><title>Results</title><p id="Par3">Diabetic patients exhibited significantly higher ECV values than controls (WMD: 2.17; 95% CI: 1.32&#x02013;3.02), consistent across subgroups excluding cardiac comorbidities (WMD: 2.02; 95% CI: 0.74&#x02013;3.31). HbA1C levels were also significantly elevated in diabetics (WMD: 1.78; 95% CI: 1.37&#x02013;2.19). However, no significant difference in native T1 values was observed (WMD: 13.40; 95% CI: -13.98&#x02013;40.79). Meta-regression revealed no significant correlation between ECV and HbA1C, potentially due to limited data and high heterogeneity (I&#x000b2;: 93.37%).</p></sec><sec><title>Conclusions</title><p id="Par4">ECV is a promising marker for quantifying MF in T2DM, demonstrating significant differences between diabetics and controls. The lack of correlation between ECV and HbA1C underscores the complexity of MF in diabetes and highlights the need for further research. Future studies with standardized protocols are essential to validate these findings and refine the use of CMR in diabetic cardiomyopathy.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12872-025-04496-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetes</kwd><kwd>Myocardial fibrosis</kwd><kwd>Extracellular volume fraction</kwd><kwd>T1 mapping</kwd><kwd>Cardiovascular magnetic resonance</kwd><kwd>Diabetic cardiomyopathy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par23">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><thead><tr><th align="left">Research Insights</th><th align="left">Summary</th></tr></thead><tbody><tr><td align="left">What is currently known about this topic?</td><td align="left">- Diabetic cardiomyopathy involves myocardial fibrosis as a key pathophysiological feature.</td></tr><tr><td align="left"/><td align="left">- ECV and native T1 mapping by CMR are non-invasive methods to quantify myocardial fibrosis.</td></tr><tr><td align="left"/><td align="left">- Myocardial fibrosis is linked to adverse cardiovascular outcomes in diabetes patients.</td></tr><tr><td align="left">What is the key research question?</td><td align="left">How do CMR-derived ECV and native T1 mapping relate to glycemic control in diabetic patients?</td></tr><tr><td align="left">What is new?</td><td align="left">- ECV is significantly elevated in diabetics vs. non-diabetics, indicating diffuse fibrosis.</td></tr><tr><td align="left"/><td align="left">- Native T1 mapping showed no significant difference between diabetics and controls.</td></tr><tr><td align="left"/><td align="left">- No correlation was found between ECV and HbA1C, underscoring complex fibrosis mechanisms.</td></tr><tr><td align="left">How might this study influence clinical practice?</td><td align="left">ECV can guide early detection and management of myocardial fibrosis in diabetic populations.</td></tr></tbody></table></table-wrap></p><sec id="Sec1"><title>Introduction</title><p id="Par24">Type 2 diabetes is a common global chronic disease that can lead to myocardial dysfunction independent of coronary artery disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. While the exact underlying pathogenesis is likely multifactorial [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>], it ultimately leads to accelerated cellular apoptosis and necrosis, causing increased perivascular and diffuse interstitial fibrosis in the myocardium [<xref ref-type="bibr" rid="CR2">2</xref>]. Notably, prior studies have provided histological evidence of heightened diffuse microscopic fibrosis in the myocardium of diabetic patients [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par25">Myocardial fibrosis (MF) is closely linked to cardiovascular events, such as heart failure (HF), coronary artery disease (CAD), atrial fibrillation (AF), and peripheral arterial disease (PAD) [<xref ref-type="bibr" rid="CR6">6</xref>]. The severity of myocardial fibrosis (MF), as measured histologically, has been independently linked to an increased risk of mortality [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. MF arises from an excessive and disproportionate buildup of collagen in the myocardial extracellular matrix [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], which can lead to reduced myocardial compliance and both diastolic and systolic dysfunction. Additionally, MF can impair impulse propagation, contributing to arrhythmias and conduction abnormalities [<xref ref-type="bibr" rid="CR11">11</xref>]. Characterized by the expansion of the myocardial interstitium, MF is now regarded as a &#x0201c;preeminent therapeutic target of the 21st century&#x0201d; [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par26">Endomyocardial biopsy is the gold standard for fibrosis assessment, but cardiovascular magnetic resonance (CMR) offers a non-invasive alternative. CMR, specifically the extracellular volume fraction (ECV) from T1-mapping, can detect interstitial fibrosis [<xref ref-type="bibr" rid="CR13">13</xref>]. ECV is a sensitive marker associated with adverse cardiovascular events.</p><p id="Par27">The primary objective of this study is to evaluate the utility of ECV and native T1 mapping as biomarkers for detecting myocardial fibrosis in patients with T2DM. Additionally, we investigate the relationship between these biomarkers and glycemic control, measured by hemoglobin A1C (HbA1C), to better understand the interplay between metabolic dysregulation and cardiac remodeling. This comprehensive meta-analysis synthesizes existing evidence to provide a clearer understanding of the role of CMR-derived parameters in diabetic cardiomyopathy and their potential clinical applications.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data sources and search strategy</title><p id="Par28">We adhered to a standardized guide for designing, conducting, and publishing systematic reviews and meta-analyses. Reporting was aligned with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We performed a comprehensive search across multiple databases, including EMBASE, Medline (Ovid), Cochrane CENTRAL, Web of Science, and Google Scholar, with the latest update occurring on May 24, 2024. Studies involving animals, conference abstracts, letters to the editor, comments, and editorials were excluded, with no restrictions on language or publication date. We also excluded studies on type 1 diabetes.</p></sec><sec id="Sec4"><title>Study selection</title><p id="Par29">Eligible studies met the following inclusion criteria: (1)&#x000a0;observational or interventional design; (2)&#x000a0;investigation of the association between diabetes status or glycemic control and myocardial fibrosis (MF), measured via CMR T1 mapping; and (3)&#x000a0;reporting of effect estimates with 95% confidence intervals, mean with standard deviations, median with interquartile ranges or p-values. Two independent reviewers screened all abstracts, and full-text articles were retrieved for studies that passed screening. Full-text assessments were also conducted by two independent reviewers, and any disagreements were resolved by consulting a third reviewer. A cross-reference search was performed using the bibliographies of included studies, applying the same inclusion criteria.</p></sec><sec id="Sec5"><title>Data extraction and quality assessment</title><p id="Par30">Study characteristics such as study design and sample size, along with participant details like age, sex, body mass index (BMI), diabetes status, glycosylated hemoglobin (HbA1C), as well as estimates of myocardial fibrosis (ECV, native T1), were documented using a predesigned data collection form.</p><p id="Par31">The primary outcomes include difference in ECV and native T1 values between diabetics and normal population. Secondary endpoints involve evaluating the correlation between these parameters and glycemic control, measured by hemoglobin A1C (HbA1C).</p><p id="Par32">Two independent reviewers evaluated each study. The quality of the studies was assessed using the Newcastle-Ottawa Scale.</p></sec><sec id="Sec6"><title>Data synthesis and analysis</title><p id="Par33">Continuous outcomes were summarized as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) to facilitate comparison. We applied Cochrane recommendations in converting median and interquartile range (IQR) to mean and standard deviation (SD). A random effects model was used to pool effect estimates from studies that reported MF using the same modality and measurement scale. Weighed mean difference was used as the effect size to measure the difference between ECV and T1 in diabetics and normal population. Correlation between glycemic control (HbA1C) and CMR parametric mapping (ECV, native T1) were addressed using meta-regression of the pooled effect sizes. Heterogeneity was assessed using the I&#x000b2; statistic: I&#x000b2; &#x02264;25% indicated low heterogeneity, 25&#x02013;75% moderate, and &#x0003e;&#x02009;75% high heterogeneity. All statistical analyses were performed using R.</p></sec><sec id="Sec7"><title>Subgroup and meta-regression analyses</title><p id="Par34">Subgroups were defined based on key variables, including imaging protocols (e.g., field strength [1.5T vs. 3T] and mapping techniques [MOLLI vs. shMOLLI]). These subgroup definitions were predetermined to account for potential sources of heterogeneity.</p><p id="Par35">For meta-regression, the included variables were selected based on their relevance to the study objectives and data availability. The primary independent variable was HbA1C, representing glycemic control. Other covariates included imaging parameters (e.g., field strength, mapping technique). The meta-regression model aimed to explore the relationship between ECV values (outcome variable) and HbA1C levels, adjusting for potential confounders. Weighted regression coefficients were calculated, and residual heterogeneity (I&#x000b2;) was assessed to determine the model&#x02019;s explanatory power. Sensitivity analyses were conducted by excluding outlier studies and re-evaluating the regression results.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Literature search</title><p id="Par36">The outcomes of the search strategy are depicted in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Out of 915 unique citations, 19 papers met the inclusion criteria. Key study characteristics are detailed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Sample sizes across studies ranged from 33 to 1176 participants, with a combined total population of 4117. The median age of participants was 57.4 years (IQR: 54.35&#x02013;62.5 years). The studies examined the association between diabetes status, glycemic control (HbA1C), and parametric CMR measures (ECV and T1). The researches were conducted across Europe (<italic>n</italic>&#x02009;=&#x02009;5), Asia (<italic>n</italic>&#x02009;=&#x02009;5), North America (<italic>n</italic>&#x02009;=&#x02009;8), and Australia (<italic>n</italic>&#x02009;=&#x02009;1). MF was assessed using cardiovascular magnetic resonance (CMR) based native T1 mapping and its derivative extracellular volume percentage (ECV%) These parametric mapping based CMR parameters in this study population were investigated at 1.5-T (<italic>n</italic>&#x02009;=&#x02009;10) and 3.0-T (<italic>n</italic>&#x02009;=&#x02009;9) MRI systems. CMR protocol of included studies are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par37">
<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA Flow Chart</p></caption><graphic xlink:href="12872_2025_4496_Fig1_HTML" id="d33e529"/></fig></p><p id="Par38">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study (ref)</th><th align="left">Country</th><th align="left">Study design</th><th align="left">
<italic>N</italic>
</th><th align="left">Study Population</th><th align="left">Mean Age</th><th align="left">Female %</th></tr></thead><tbody><tr><td align="left">Al-Badri 2018 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">USA</td><td align="left">Case control</td><td char="." align="char">47</td><td align="left">Patients from veteran&#x02019;s hospital</td><td align="left">65.8</td><td align="left">11</td></tr><tr><td align="left">Cao 2018 [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">China</td><td align="left">Case control</td><td align="left">82</td><td align="left">Patients in tertiary hospital and community controls</td><td align="left">54.6</td><td align="left">45</td></tr><tr><td align="left">Chirinos 2019 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">USA</td><td align="left">Secondary analysis of baseline data from a previous phase 2 randomized controlled trial (RCT)</td><td char="." align="char">53</td><td align="left">Subjects with symptomatic HFpEF (LVEF&#x02009;&#x0003e;&#x02009;50%) were included based on specific clinical criteria (e.g., previous HF hospitalization, elevated NT-proBNP)</td><td align="left">64 (median)</td><td align="left">24.52</td></tr><tr><td align="left">Dennis 2022 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">Australia</td><td align="left">Case control</td><td char="." align="char">67</td><td align="left">Patients were recruited from the Royal Prince Alfred Hospital (RPAH) Diabetes Centre &#x02013; a university teaching hospital, outpatient diabetes service.</td><td align="left">61 (median)</td><td align="left">39</td></tr><tr><td align="left">Gao 2019 [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">China</td><td align="left">Case control</td><td char="." align="char">100</td><td align="left">Patients in tertiary hospital and healthy volunteers</td><td align="left">57.4</td><td align="left">59</td></tr><tr><td align="left">Gulsin 2019 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">United Kingdom</td><td align="left">Prospective cohort</td><td char="." align="char">96</td><td align="left">HFpEF cases from outpatient and inpatient clinics</td><td align="left">72.3</td><td align="left">51</td></tr><tr><td align="left">Jiang 2020 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">USA</td><td align="left">Prospective cohort</td><td char="." align="char">190</td><td align="left">Patients from a tertiary hospital and healthy control subjects</td><td align="left">55.6</td><td align="left">37</td></tr><tr><td align="left">Khan 2020 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">USA</td><td align="left">Case control</td><td char="." align="char">442</td><td align="left">Patients referred for CMR at tertiary hospital</td><td align="left">60.2</td><td align="left">52</td></tr><tr><td align="left">Kim 2022 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">Republic of Korea</td><td align="left">Case control</td><td char="." align="char">233</td><td align="left">Asymptomatic subjects who underwent CMR for health screening at tertiary hospital</td><td align="left">54.1</td><td align="left">9.8</td></tr><tr><td align="left">Kropidlowski 2020 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">Germany</td><td align="left">Retrospective cohort</td><td char="." align="char">63</td><td align="left">Patients with well-treated hypertension and healthy volunteers</td><td align="left">58.7</td><td align="left">49.2</td></tr><tr><td align="left">Kucukseymen 2020 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">USA</td><td align="left">Retrospective cohort</td><td char="." align="char">207</td><td align="left">Patients with diabetes, obesity, or both and healthy control subjects</td><td align="left">55.6</td><td align="left">61</td></tr><tr><td align="left">Lam 2019 [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">USA</td><td align="left">Case control</td><td char="." align="char">37</td><td align="left">Patients from endocrinology clinic and community control subjects</td><td align="left">49.5</td><td align="left">70</td></tr><tr><td align="left">Laohabut 2021 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">Thailand</td><td align="left">Retrospective cohort</td><td char="." align="char">739</td><td align="left">Patients with known or suspected coronary artery disease who underwent CMR at a tertiary hospital</td><td align="left">69.5</td><td align="left">50.7</td></tr><tr><td align="left">Levelt 2016 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">United Kingdom</td><td align="left">Prospective observational study</td><td char="." align="char">66</td><td align="left">Patients with DM in general practice clinics and community control subjects</td><td align="left">54.7</td><td align="left">51</td></tr><tr><td align="left">Liu 2022 [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">China</td><td align="left">Case control</td><td char="." align="char">122</td><td align="left">Patients who were diagnosed with T2DM in the Department of Endocrinology at tertiary hospital</td><td align="left">53.18</td><td align="left">41</td></tr><tr><td align="left">Shah 2013 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">USA</td><td align="left">Prospective cohort</td><td char="." align="char">33</td><td align="left">Obese adolescents in a tertiary hospital and healthy volunteers</td><td align="left">16.8</td><td align="left">51.5</td></tr><tr><td align="left">Storz 2018 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">Germany</td><td align="left">Case control</td><td char="." align="char">343</td><td align="left">General population</td><td align="left">59.1</td><td align="left">31</td></tr><tr><td align="left">Swoboda 2017 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">United Kingdom</td><td align="left">Case control</td><td char="." align="char">130</td><td align="left">Patients in general practice clinics and community control subjects</td><td align="left">60.3</td><td align="left">21</td></tr><tr><td align="left">Wong 2014 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">USA</td><td align="left">Case control</td><td char="." align="char">1176</td><td align="left">Patients referred for CMR at tertiary hospital</td><td align="left">54.6</td><td align="left">41</td></tr></tbody></table></table-wrap></p><p id="Par39">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>CMR Protocol of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study (ref)</th><th align="left">MRI Field Strength</th><th align="left">Vendor</th><th align="left">T1 mapping technique</th></tr></thead><tbody><tr><td align="left">Al-Badri 2018 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Cao 2018 [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Chirinos 2019 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Dennis 2022 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">1.5</td><td align="left">Achieva, Philips Healthcare, Best, The Netherlands</td><td align="left">MOLLI</td></tr><tr><td align="left">Gao 2019 [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">3</td><td align="left"><p>Skrya; Siemens</p><p>Medical Solutions, Erlangen, Germany</p></td><td align="left">MOLLI</td></tr><tr><td align="left">Gulsin 2019 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">3</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">shMOLLI</td></tr><tr><td align="left">Jiang 2020 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">3</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Khan 2020 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">Both</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Kim 2022 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">1.5</td><td align="left">Siemens Healthineers</td><td align="left">MOLLI</td></tr><tr><td align="left">Kropidlowski 2020 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Kucukseymen 2020 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Lam 2019 [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Imaging Solutions, Erlanger, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Laohabut 2021 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">3</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">shMOLLI</td></tr><tr><td align="left">Levelt 2016 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">3</td><td align="left">Siemens, Germany</td><td align="left">shMOLLI</td></tr><tr><td align="left">Liu 2022 [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">3</td><td align="left"><p>Skyra, Siemens</p><p>Medical Solutions</p></td><td align="left">MOLLI</td></tr><tr><td align="left">Shah 2013 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">3</td><td align="left">Siemens Verio, Siemens, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Storz 2018 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">3</td><td align="left">Siemens AG, Healthcare Sector, Erlangen, Germany</td><td align="left">MOLLI</td></tr><tr><td align="left">Swoboda 2017 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">3</td><td align="left">Achieva system, Tesla Philips</td><td align="left">MOLLI</td></tr><tr><td align="left">Wong 2014 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">1.5</td><td align="left">Siemens Medical Solutions, Erlangen, Germany</td><td align="left">MOLLI</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Quality and risk of bias assesment</title><p id="Par40">The risk of bias in observational studies varied from low (24%), to moderate (34%), to high (42%) (Supplemental Table 1). The quality of the included studies varied significantly, as reflected by their Newcastle-Ottawa Scale (NOS) scores. High-quality studies (NOS scores of 7 or 8, e.g., Jiang 2020, Kucukseymen 2020, Storz 2018) demonstrated robust methodologies and comprehensive reporting, contributing to the reliability of pooled estimates. Conversely, studies rated as poor (e.g., Al-Badri 2018, Lam 2019) often exhibited limitations in selection criteria or comparability, which may have introduced bias.</p></sec><sec id="Sec11"><title>Diabetes and ECV &#x00026; T1</title><p id="Par41">Figures&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>, <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig6" ref-type="fig">6</xref> investigate if the weighed mean difference (WMD) of the investigated parameters of our study (ECV, native T1, and HbA1C) between the study groups (diabetics VS control subjects).</p><p id="Par42">Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> demonstrates a significantly higher ECV values among the cases compared to the controls (WMD: 2.17; 95% CI: 1.32 to 3.02). We performed a separate analysis for the studies which excluded patients with a history of any cardiac disease or MI which showed the same findings (WMD: 2.02; 95% CI: 0.74 to 3.31) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The same applies for HbA1C values (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>), which are expectedly higher among the cases (WMD: 1.78; 95% CI: 1.37 to 2.19). This suggests a potential correlation between ECV and DM control (as estimated by the HbA1C lab values). As for native T1 values (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), no statistically significant difference between the two groups was detected (WMD: 13.40; 95% CI: &#x02212;13.98 to 40.79). Additional analysis of studies excluding patients with a history of any cardiac disease or MI showed the same findings (WMD: 11.88; 95% CI: &#x02212;17.35 to 41.11) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). However, significant heterogeneity was present in all the analyses.</p><p id="Par43">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows results from the meta-regression model fit to assess the correlation between ECV values (outcome variable) and HbA1C (independent predictor variable) while accounting for not only the weighed values for the two parameters, but also their corresponding variance. As noted below, it appears that no significant correlation between ECV and HbA1C could be detected (p-value: 0.5064). The interpretation of these findings should be done with highest caution. One reason for this is the fact that the meta-regression model could potentially be underpowered since only few of the included studies have reported the HbA1C values for the two study arms (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Another reason is the notably high residual heterogeneity (I^2: 93.37%), which suggests that the model selection requires more thoughtful reconsideration.</p><p id="Par44">
<fig id="Fig2"><label>Fig. 2</label><caption><p>WMD of ECV values between the study arms: Statistically significant difference in ECV was found between diabetics and normal populations (WMD: 2.17; 95% CI: 1.32 to 3.02)</p></caption><graphic xlink:href="12872_2025_4496_Fig2_HTML" id="d33e1257"/></fig></p><p id="Par45">
<fig id="Fig3"><label>Fig. 3</label><caption><p>WMD of ECV values between the study arms (Studies with any history of cardiac disease excluded): Statistically significant difference in ECV was found between diabetics and normal populations (WMD: 2.02; 95% CI: 0.74 to 3.31)</p></caption><graphic xlink:href="12872_2025_4496_Fig3_HTML" id="d33e1266"/></fig></p><p id="Par46">
<fig id="Fig4"><label>Fig. 4</label><caption><p>WMD of native T1 values between the study arms: No statistically significant difference in native T1 was found between diabetics and normal populations (WMD: 13.40; 95% CI: &#x02212;13.98 to 40.79)</p></caption><graphic xlink:href="12872_2025_4496_Fig4_HTML" id="d33e1275"/></fig></p><p id="Par47">
<fig id="Fig5"><label>Fig. 5</label><caption><p>WMD of native T1 values between the study arms (Studies with any history of cardiac disease excluded): No statistically significant difference in native T1 was found between diabetics and normal populations (WMD: 11.88; 95% CI: &#x02212;17.35 to 41.11)</p></caption><graphic xlink:href="12872_2025_4496_Fig5_HTML" id="d33e1284"/></fig></p><p id="Par48">
<fig id="Fig6"><label>Fig. 6</label><caption><p>WMD of HbA1C values between the study arms. Statistically significant difference in HbA1C was found between diabetics and normal populations (WMD: 1.78; 95% CI: 1.37 to 2.19)</p></caption><graphic xlink:href="12872_2025_4496_Fig6_HTML" id="d33e1293"/></fig></p><p id="Par49">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>A meta regression model assessing the correlation between weighed mean ECV values and HbA1C values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Estimate</th><th align="left">Standard Error</th><th align="left">z-value</th><th align="left"><italic>p</italic>-value</th><th align="left">Confidence Interval (Lower Bound)</th><th align="left">Confidence Interval (Upper Bound)</th><th align="left">Significance</th></tr></thead><tbody><tr><td align="left">
<bold>Intercept</bold>
</td><td char="." align="char">&#x02212;0.2240</td><td char="." align="char">1.9890</td><td char="." align="char">&#x02212;0.1126</td><td char="." align="char">0.9103</td><td char="." align="char">&#x02212;4.1224</td><td char="." align="char">3.6743</td><td align="left"/></tr><tr><td align="left">
<bold>HbA1C yi</bold>
</td><td char="." align="char">0.8823</td><td char="." align="char">1.3280</td><td char="." align="char">0.6644</td><td char="." align="char">0.5064</td><td char="." align="char">&#x02212;1.7206</td><td char="." align="char">3.4852</td><td align="left"/></tr><tr><td align="left">
<bold>HbA1C vi</bold>
</td><td char="." align="char">8.0057</td><td char="." align="char">26.0020</td><td char="." align="char">0.3079</td><td char="." align="char">0.7582</td><td char="." align="char">&#x02212;42.9574</td><td char="." align="char">58.9688</td><td align="left"/></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Sensitivity &#x00026; subgroup analyses</title><p id="Par50">To address the significant heterogeneity, we performed sensitivity and subgroup analyses based on field strength and T1 mapping technique (Supplemental Figs.&#x000a0;1&#x02013;8). However, neither the sensitivity analyses nor the subgroup analyses were able to resolve the heterogeneity in both the ECV and native T1 analyses. Only the sub-analysis of studies using ShMOLLI showed no significant heterogeneity, possibly due to the small number of studies (three) that used this technique. Therefore, our results should be interpreted with caution.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par51">This meta-analysis sheds lights on the relationship between myocardial fibrosis, as measured by ECV, and diabetes mellitus (DM). Our findings confirm that diabetic patients exhibit significantly higher ECV values compared to controls, indicating an increased degree of myocardial fibrosis. This aligns with previous studies that have identified myocardial fibrosis as a common complication of chronic hyperglycemia, contributing to the increased cardiovascular morbidity in this population [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par52">Although ECV values were elevated in patients with diabetes, our analysis did not find a significant difference in native T1 values between these patients and controls, despite a similar trend. This is likely due to the small sample size of the included studies. Therefore, the meta-analysis of native T1 time studies may have lacked sufficient power, as the ECV% meta-analysis included a larger sample size. There are several explanations for the results of the T1 time meta-analysis. First, the native T1 time parameter shows weaker correlation with histology compared to ECV% [<xref ref-type="bibr" rid="CR13">13</xref>]. Additionally, a cohort study demonstrated that abnormal ECV was more strongly associated with adverse outcomes than native T1 time [<xref ref-type="bibr" rid="CR33">33</xref>]. Moreover, native T1 time estimates reflect changes across the entire myocardium and may lack sensitivity to detect interstitial-specific alterations [<xref ref-type="bibr" rid="CR34">34</xref>]. Native T1 time is also more affected by patient characteristics compared to ECV% [<xref ref-type="bibr" rid="CR35">35</xref>], . For example, in a study where ECV was normal, native T1 times were elevated in patients with diabetes, suggesting a potential influence of diabetes on T1 time parameters independent of MF [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par53">Our meta-regression analysis aimed to explore the potential correlation between ECV and HbA1C levels as a measure of diabetes control. However, no significant correlation was found, despite the clear association between higher ECV values and increased variance in HbA1C. The observed lack of significant correlation between HbA1C and ECV may be attributed to several factors. First, the limited sample size of studies reporting HbA1C data for both study arms could result in insufficient statistical power to detect a meaningful relationship. Second, substantial heterogeneity across studies, including variations in patient populations (e.g., diabetes duration, degree of glycemic control) and imaging methodologies, may obscure potential correlations. Variations in study design could also explain the lack of a significant finding. For instance, cross-sectional studies capture data at a single time point, which may not adequately reflect the dynamic relationship between glycemic control and myocardial fibrosis. Furthermore, HbA1C reflects long-term glycemic averages but does not capture acute fluctuations in glucose levels, which might play a more direct role in fibrotic remodeling. Additionally, the mechanisms driving myocardial fibrosis in diabetes are multifactorial and not solely dependent on hyperglycemia. Other factors, such as inflammation, advanced glycation end-products (AGEs), and oxidative stress, could independently contribute to fibrosis, diminishing the observed association between HbA1C and ECV.</p><p id="Par54">Notably, Hajdu et al. (2022) demonstrated a significant correlation between HbA1C levels and strain parameters obtained through echocardiography [<xref ref-type="bibr" rid="CR36">36</xref>]. This suggests that certain cardiac imaging techniques may be more sensitive to glycemic control&#x02019;s impact on myocardial function. Differences in imaging modalities, sensitivity to subclinical changes, and study populations could explain these discrepancies. Comparative analyses integrating various imaging methods, such as strain echocardiography and CMR, may help reconcile these findings.</p><p id="Par55">Our findings underscore the complexity of myocardial fibrosis in diabetic patients and the need for more robust and consistent data to better understand the relationship between DM control and myocardial fibrosis. While ECV appears to be a promising marker for assessing fibrosis in diabetic populations, the variability in the association with HbA1C highlights the need for caution in interpreting these results. One potential confounding factor is the reason why CMR was done in different studies. Future studies with larger sample sizes and more consistent reporting of relevant clinical parameters are essential to confirm these findings and refine the use of ECV as a diagnostic tool. If validated, these findings could have clinical significance, as a greater extent of myocardial fibrosis (MF) has been linked to a higher risk of adverse events [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Studies utilizing histology to measure MF have shown that each unit increase in collagen volume fraction (CVF) was associated with up to a 28% higher risk of cardiac events and a 50% increase in all-cause mortality. Similarly, for each unit increase in extracellular volume (ECV%), there was a 30% increased risk of recurrent atrial fibrillation (AF) and a 16% higher risk of composite heart failure hospitalization (HHF) or all-cause mortality [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par56">In terms of clinical applications, elevated ECV values in diabetic individuals suggest its potential applicability in early detection of myocardial fibrosis, even in asymptomatic stages of the disease. These biomarkers could be incorporated into routine CMR imaging protocols in the future to identify patients at higher risk of adverse cardiac outcomes, such as heart failure or arrhythmias. In clinical practice, ECV mapping may guide treatment decisions by stratifying patients based on the degree of myocardial fibrosis. For instance, patients with significantly elevated ECV values might benefit from more aggressive glycemic control, antifibrotic therapies, or interventions targeting associated metabolic and inflammatory pathways. Additionally, these biomarkers could serve as endpoints in clinical trials evaluating novel therapies for diabetic cardiomyopathy. Risk stratification using ECV could also inform the frequency of follow-up and imaging assessments, prioritizing high-risk patients for more intensive monitoring. Moreover, combining ECV with other clinical data, such as biomarkers of inflammation or endothelial dysfunction, could provide a comprehensive approach to personalized care for diabetic patients.</p><p id="Par57">While native T1 mapping shows potential as a tool for characterizing myocardial tissue properties, the current evidence is inconclusive due to this lack of significance and high heterogeneity across studies. Consequently, its clinical utility requires further validation through standardized protocols and larger studies.</p><p id="Par58">Several limitations should be noted. The studies examining diabetes and myocardial fibrosis (MF) were either cross-sectional or observational, meaning the possibility of reverse causation or bidirectional relationships cannot be ruled out. Additionally, some of the included studies were assessed as being of poor quality. The variability in study quality underscores the need for caution when interpreting pooled results. However, even after excluding these lower-quality studies from our analysis, our findings remained consistent.</p><p id="Par59">For native T1 analysis, the meta-analysis may have been underpowered due to the limited number of studies and substantial heterogeneity. Contributing factors include differences in imaging protocols (e.g., MOLLI vs. ShMOLLI techniques), field strength (1.5T vs. 3T), and patient populations (e.g., age, presence of cardiac comorbidities, glycemic control). Variability in study designs and sample sizes may also contribute. Sensitivity and subgroup analyses failed to resolve the heterogeneity, highlighting the need for further research to better understand native T1&#x02019;s role in diabetic cardiomyopathy.</p><p id="Par60">To address these limitations, future studies should aim to standardize imaging protocols, including field strength and T1 mapping techniques, to minimize variability. Consistent reporting of patient characteristics, such as diabetes duration and severity, would enhance comparability across studies. Additionally, larger sample sizes and longitudinal study designs could help clarify the relationship between myocardial fibrosis markers and diabetes severity. Addressing these gaps will be crucial for improving the clinical applicability of both ECV and native T1 mapping in diabetic populations.</p><p id="Par61">In conclusion, while our analysis supports the use of ECV as a marker of myocardial fibrosis in diabetics, the relationship between ECV and DM severity remains unclear. Further research is needed to fully elucidate the clinical implications of these findings and to determine the most effective imaging strategies for detecting and monitoring myocardial fibrosis in diabetic patients.</p></sec><sec id="Sec222" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12872_2025_4496_MOESM1_ESM.docx"><caption><p>Additional file 1.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>T2DM</term><def><p id="Par5">Type 2 Diabetes Mellitus</p></def></def-item><def-item><term>MF</term><def><p id="Par6">Myocardial Fibrosis</p></def></def-item><def-item><term>CMR</term><def><p id="Par7">Cardiovascular Magnetic Resonance</p></def></def-item><def-item><term>ECV</term><def><p id="Par8">Extracellular Volume Fraction</p></def></def-item><def-item><term>HbA1C</term><def><p id="Par9">Hemoglobin A1C</p></def></def-item><def-item><term>T1</term><def><p id="Par10">Native T1 Mapping</p></def></def-item><def-item><term>WMD</term><def><p id="Par11">Weighted Mean Difference</p></def></def-item><def-item><term>CAD</term><def><p id="Par12">Coronary Artery Disease</p></def></def-item><def-item><term>HF</term><def><p id="Par13">Heart Failure</p></def></def-item><def-item><term>PAD</term><def><p id="Par14">Peripheral Arterial Disease</p></def></def-item><def-item><term>AF</term><def><p id="Par15">Atrial Fibrillation</p></def></def-item><def-item><term>SD</term><def><p id="Par16">Standard Deviation</p></def></def-item><def-item><term>IQR</term><def><p id="Par17">Interquartile Range</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par18">Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></def></def-item><def-item><term>NT-proBNP</term><def><p id="Par19">N-terminal Prohormone of Brain Natriuretic Peptide</p></def></def-item><def-item><term>LVEF</term><def><p id="Par20">Left Ventricular Ejection Fraction</p></def></def-item><def-item><term>HHF</term><def><p id="Par21">Heart Failure Hospitalization</p></def></def-item><def-item><term>CVF</term><def><p id="Par22">Collagen Volume Fraction</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>A.M. and M.U. conceptualized and designed the study. A.M., A.A., and F.A. conducted the literature search and data extraction. H.G. and J.A. performed the statistical analyses. A.N. and H.G. contributed to the interpretation of data. A.M. wrote the initial manuscript draft, with critical revisions and input from all authors. Figures and tables were prepared by H.G. and F.A. All authors reviewed and approved the final manuscript and are accountable for the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data and materials supporting the findings of this meta-analysis are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par62">Not applicable. All used data was publicly available.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par63">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par64">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Marwick</surname><given-names>TH</given-names></name></person-group><article-title>The diabetic myocardium</article-title><source>Curr Diab Rep</source><year>2006</year><volume>6</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s11892-006-0049-0</pub-id><pub-id pub-id-type="pmid">16522279</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Marwick TH. The diabetic myocardium. Curr Diab Rep. 2006;6(1):36&#x02013;41.<pub-id pub-id-type="pmid">16522279</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Aneja</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Bansilal</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>MJ</given-names></name><name><surname>Farkouh</surname><given-names>ME</given-names></name></person-group><article-title>Diabetic Cardiomyopathy: insights into Pathogenesis, Diagnostic challenges, and Therapeutic options</article-title><source>Am J Med</source><year>2008</year><volume>121</volume><issue>9</issue><fpage>748</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2008.03.046</pub-id><pub-id pub-id-type="pmid">18724960</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Aneja A, Tang WHW, Bansilal S, Garcia MJ, Farkouh ME. Diabetic Cardiomyopathy: insights into Pathogenesis, Diagnostic challenges, and Therapeutic options. Am J Med. 2008;121(9):748&#x02013;57.<pub-id pub-id-type="pmid">18724960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Shivu</surname><given-names>GN</given-names></name><name><surname>Phan</surname><given-names>TT</given-names></name><name><surname>Abozguia</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Wagenmakers</surname><given-names>A</given-names></name><name><surname>Henning</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relationship between coronary microvascular dysfunction and Cardiac Energetics Impairment in type 1 diabetes Mellitus</article-title><source>Circulation</source><year>2010</year><volume>121</volume><issue>10</issue><fpage>1209</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.873273</pub-id><pub-id pub-id-type="pmid">20194884</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Shivu GN, Phan TT, Abozguia K, Ahmed I, Wagenmakers A, Henning A, et al. Relationship between coronary microvascular dysfunction and Cardiac Energetics Impairment in type 1 diabetes Mellitus. Circulation. 2010;121(10):1209&#x02013;15.<pub-id pub-id-type="pmid">20194884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Konduracka</surname><given-names>E</given-names></name><name><surname>Gackowski</surname><given-names>A</given-names></name><name><surname>Rostoff</surname><given-names>P</given-names></name><name><surname>Galicka-Latala</surname><given-names>D</given-names></name><name><surname>Frasik</surname><given-names>W</given-names></name><name><surname>Piwowarska</surname><given-names>W</given-names></name></person-group><article-title>Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>20</issue><fpage>2465</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehm361</pub-id><pub-id pub-id-type="pmid">17766928</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J. 2007;28(20):2465&#x02013;71.<pub-id pub-id-type="pmid">17766928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Kajstura</surname><given-names>J</given-names></name><name><surname>Chimenti</surname><given-names>C</given-names></name><name><surname>Jakoniuk</surname><given-names>I</given-names></name><name><surname>Leri</surname><given-names>A</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Myocardial cell death in human diabetes</article-title><source>Circ Res</source><year>2000</year><volume>87</volume><issue>12</issue><fpage>1123</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1161/01.RES.87.12.1123</pub-id><pub-id pub-id-type="pmid">11110769</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87(12):1123&#x02013;32.<pub-id pub-id-type="pmid">11110769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Ambale-Venkatesh</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Donekal</surname><given-names>S</given-names></name><name><surname>Ohyama</surname><given-names>Y</given-names></name><name><surname>Sharma</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis</article-title><source>Eur Heart J - Cardiovasc Imaging</source><year>2019</year><volume>20</volume><issue>2</issue><fpage>168</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jey140</pub-id><pub-id pub-id-type="pmid">30325426</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ambale-Venkatesh B, Liu CY, Liu YC, Donekal S, Ohyama Y, Sharma RK, et al. Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis. Eur Heart J - Cardiovasc Imaging. 2019;20(2):168&#x02013;76.<pub-id pub-id-type="pmid">30325426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Schelbert</surname><given-names>EB</given-names></name><name><surname>Piehler</surname><given-names>KM</given-names></name><name><surname>Zareba</surname><given-names>KM</given-names></name><name><surname>Moon</surname><given-names>JC</given-names></name><name><surname>Ugander</surname><given-names>M</given-names></name><name><surname>Messroghli</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Myocardial fibrosis quantified by Extracellular volume is Associated with subsequent hospitalization for heart failure, death, or both across the Spectrum of Ejection Fraction and Heart failure stage</article-title><source>J Am Heart Assoc</source><year>2015</year><volume>4</volume><issue>12</issue><fpage>e002613</fpage><pub-id pub-id-type="doi">10.1161/JAHA.115.002613</pub-id><pub-id pub-id-type="pmid">26683218</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR, et al. Myocardial fibrosis quantified by Extracellular volume is Associated with subsequent hospitalization for heart failure, death, or both across the Spectrum of Ejection Fraction and Heart failure stage. J Am Heart Assoc. 2015;4(12):e002613.<pub-id pub-id-type="pmid">26683218</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Fukumoto</surname><given-names>Y</given-names></name><name><surname>Sugimura</surname><given-names>K</given-names></name><name><surname>Oikawa</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic impact of myocardial interstitial fibrosis in Non-ischemic Heart failure</article-title><source>Circ J</source><year>2011</year><volume>75</volume><issue>11</issue><fpage>2605</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-11-0568</pub-id><pub-id pub-id-type="pmid">21821961</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, et al. Prognostic impact of myocardial interstitial fibrosis in Non-ischemic Heart failure. Circ J. 2011;75(11):2605&#x02013;13.<pub-id pub-id-type="pmid">21821961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>I</given-names></name><name><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group><article-title>Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities</article-title><source>J Mol Cell Cardiol</source><year>2016</year><volume>90</volume><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.12.011</pub-id><pub-id pub-id-type="pmid">26705059</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84&#x02013;93.<pub-id pub-id-type="pmid">26705059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>KT</given-names></name><name><surname>Brilla</surname><given-names>CG</given-names></name></person-group><article-title>Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system</article-title><source>Circulation</source><year>1991</year><volume>83</volume><issue>6</issue><fpage>1849</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.83.6.1849</pub-id><pub-id pub-id-type="pmid">1828192</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83(6):1849&#x02013;65.<pub-id pub-id-type="pmid">1828192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group><article-title>The Extracellular Matrix in ischemic and nonischemic heart failure</article-title><source>Circ Res</source><year>2019</year><volume>125</volume><issue>1</issue><fpage>117</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.311148</pub-id><pub-id pub-id-type="pmid">31219741</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Frangogiannis NG. The Extracellular Matrix in ischemic and nonischemic heart failure. Circ Res. 2019;125(1):117&#x02013;46.<pub-id pub-id-type="pmid">31219741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Schelbert</surname><given-names>EB</given-names></name><name><surname>Chandrashekhar</surname><given-names>Y</given-names></name></person-group><article-title>The myocardial interstitium: the principal therapeutic target of the 21st Century?</article-title><source>JACC Cardiovasc Imaging</source><year>2019</year><volume>12</volume><issue>11Part2</issue><fpage>2369</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2019.10.002</pub-id><pub-id pub-id-type="pmid">31699304</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Schelbert EB, Chandrashekhar Y. The myocardial interstitium: the principal therapeutic target of the 21st Century? JACC Cardiovasc Imaging. 2019;12(11Part2):2369&#x02013;71.<pub-id pub-id-type="pmid">31699304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Diao Kyue, Yang Z gang, Xu Hyan, Liu X, Zhang Q, Shi K et al. Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson. 2016;18(1):92.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Badri</surname><given-names>A</given-names></name><name><surname>Hashmath</surname><given-names>Z</given-names></name><name><surname>Oldland</surname><given-names>GH</given-names></name><name><surname>Miller</surname><given-names>R</given-names></name><name><surname>Javaid</surname><given-names>K</given-names></name><name><surname>Syed</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Poor glycemic control is Associated with increased extracellular volume fraction in diabetes</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><issue>9</issue><fpage>2019</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2337/dc18-0324</pub-id><pub-id pub-id-type="pmid">30002196</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Al-Badri A, Hashmath Z, Oldland GH, Miller R, Javaid K, Syed AA, et al. Poor glycemic control is Associated with increased extracellular volume fraction in diabetes. Diabetes Care. 2018;41(9):2019&#x02013;25.<pub-id pub-id-type="pmid">30002196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain</article-title><source>Cardiovasc Diabetol</source><year>2018</year><volume>17</volume><issue>1</issue><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0651-2</pub-id><pub-id pub-id-type="pmid">29301529</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cao Y, Zeng W, Cui Y, Kong X, Wang M, Yu J, et al. Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain. Cardiovasc Diabetol. 2018;17(1):7.<pub-id pub-id-type="pmid">29301529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chirinos</surname><given-names>JA</given-names></name><name><surname>Bhattacharya</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Proto</surname><given-names>E</given-names></name><name><surname>Konda</surname><given-names>P</given-names></name><name><surname>Segers</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of diabetes Mellitus on Ventricular structure, arterial stiffness, and Pulsatile Hemodynamics in Heart failure with preserved ejection fraction</article-title><source>J Am Heart Assoc</source><year>2019</year><volume>8</volume><issue>4</issue><fpage>e011457</fpage><pub-id pub-id-type="doi">10.1161/JAHA.118.011457</pub-id><pub-id pub-id-type="pmid">30764699</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chirinos JA, Bhattacharya P, Kumar A, Proto E, Konda P, Segers P, et al. Impact of diabetes Mellitus on Ventricular structure, arterial stiffness, and Pulsatile Hemodynamics in Heart failure with preserved ejection fraction. J Am Heart Assoc. 2019;8(4):e011457.<pub-id pub-id-type="pmid">30764699</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Howpage</surname><given-names>S</given-names></name><name><surname>McGill</surname><given-names>M</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Koay</surname><given-names>Y</given-names></name><name><surname>Nguyen-Lal</surname><given-names>L</given-names></name><etal/></person-group><article-title>Myocardial fibrosis in type 2 diabetes is associated with functional and metabolomic parameters</article-title><source>Int J Cardiol</source><year>2022</year><volume>363</volume><fpage>179</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2022.06.049</pub-id><pub-id pub-id-type="pmid">35724800</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Dennis M, Howpage S, McGill M, Dutta S, Koay Y, Nguyen-Lal L, et al. Myocardial fibrosis in type 2 diabetes is associated with functional and metabolomic parameters. Int J Cardiol. 2022;363:179&#x02013;84.<pub-id pub-id-type="pmid">35724800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>ZG</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Evaluation of myocardial fibrosis in diabetes with cardiac magnetic resonance T1-mapping: correlation with the high-level hemoglobin A1c</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>150</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2019.03.004</pub-id><pub-id pub-id-type="pmid">30844469</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gao Y, Yang ZG, Ren Y, Liu X, Jiang L, Xie LJ, et al. Evaluation of myocardial fibrosis in diabetes with cardiac magnetic resonance T1-mapping: correlation with the high-level hemoglobin A1c. Diabetes Res Clin Pract. 2019;150:72&#x02013;80.<pub-id pub-id-type="pmid">30844469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Gulsin</surname><given-names>GS</given-names></name><name><surname>Kanagala</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>DCS</given-names></name><name><surname>Cheng</surname><given-names>ASH</given-names></name><name><surname>Athithan</surname><given-names>L</given-names></name><name><surname>Graham-Brown</surname><given-names>MPM</given-names></name><etal/></person-group><article-title>Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes</article-title><source>Ther Adv Endocrinol Metab</source><year>2019</year><volume>10</volume><fpage>2042018819861593</fpage><pub-id pub-id-type="doi">10.1177/2042018819861593</pub-id><pub-id pub-id-type="pmid">31308926</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gulsin GS, Kanagala P, Chan DCS, Cheng ASH, Athithan L, Graham-Brown MPM, et al. Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. Ther Adv Endocrinol Metab. 2019;10:2042018819861593.<pub-id pub-id-type="pmid">31308926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>ZL</given-names></name><name><surname>Xia</surname><given-names>CC</given-names></name><name><surname>Xie</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>The combined effects of cardiac geometry, microcirculation, and tissue characteristics on cardiac systolic and diastolic function in subclinical diabetes mellitus-related cardiomyopathy</article-title><source>Int J Cardiol</source><year>2020</year><volume>320</volume><fpage>112</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2020.07.013</pub-id><pub-id pub-id-type="pmid">32679137</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jiang L, Wang J, Liu X, Li ZL, Xia CC, Xie LJ, et al. The combined effects of cardiac geometry, microcirculation, and tissue characteristics on cardiac systolic and diastolic function in subclinical diabetes mellitus-related cardiomyopathy. Int J Cardiol. 2020;320:112&#x02013;8.<pub-id pub-id-type="pmid">32679137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Yang</surname><given-names>EY</given-names></name><name><surname>Nguyen</surname><given-names>DT</given-names></name><name><surname>Nabi</surname><given-names>F</given-names></name><name><surname>Hinojosa</surname><given-names>J</given-names></name><name><surname>Jabel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Examining the relationship and Prognostic Implication of Diabetic Status and Extracellular Matrix expansion by Cardiac magnetic resonance</article-title><source>Circ Cardiovasc Imaging</source><year>2020</year><volume>13</volume><issue>7</issue><fpage>e011000</fpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.120.011000</pub-id><pub-id pub-id-type="pmid">32673493</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Khan MA, Yang EY, Nguyen DT, Nabi F, Hinojosa J, Jabel M, et al. Examining the relationship and Prognostic Implication of Diabetic Status and Extracellular Matrix expansion by Cardiac magnetic resonance. Circ Cardiovasc Imaging. 2020;13(7):e011000.<pub-id pub-id-type="pmid">32673493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Cho</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Paek</surname><given-names>M</given-names></name><etal/></person-group><article-title>T1 values and extracellular volume fraction in asymptomatic subjects: variations in left ventricular segments and correlation with cardiovascular risk factors</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><fpage>12544</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-16696-0</pub-id><pub-id pub-id-type="pmid">35869106</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Kim MY, Cho SJ, Kim HJ, Kim SM, Lee SC, Paek M, et al. T1 values and extracellular volume fraction in asymptomatic subjects: variations in left ventricular segments and correlation with cardiovascular risk factors. Sci Rep. 2022;12:12544.<pub-id pub-id-type="pmid">35869106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Kropidlowski C, Meier-Schroers M, Kuetting D, Sprinkart A, Schild H, Thomas D et al. CMR based measurement of aortic stiffness, epicardial fat, left ventricular myocardial strain and fibrosis in hypertensive patients. Int J Cardiol Heart Vasc. 2020 Apr;27. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026624/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026624/</ext-link>. Cited 2024 Sep 29.</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Kucukseymen</surname><given-names>S</given-names></name><name><surname>Neisius</surname><given-names>U</given-names></name><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Tsao</surname><given-names>CW</given-names></name><name><surname>Nezafat</surname><given-names>R</given-names></name></person-group><article-title>Negative synergism of diabetes mellitus and obesity in patients with heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study</article-title><source>Int J Cardiovasc Imaging</source><year>2020</year><volume>36</volume><issue>10</issue><fpage>2027</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s10554-020-01915-4</pub-id><pub-id pub-id-type="pmid">32533279</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kucukseymen S, Neisius U, Rodriguez J, Tsao CW, Nezafat R. Negative synergism of diabetes mellitus and obesity in patients with heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study. Int J Cardiovasc Imaging. 2020;36(10):2027&#x02013;38.<pub-id pub-id-type="pmid">32533279</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>B</given-names></name><name><surname>Stromp</surname><given-names>TA</given-names></name><name><surname>Hui</surname><given-names>Z</given-names></name><name><surname>Vandsburger</surname><given-names>M</given-names></name></person-group><article-title>Myocardial native-T1 times are elevated as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis</article-title><source>Magn Reson Imaging</source><year>2019</year><volume>61</volume><fpage>83</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2019.05.029</pub-id><pub-id pub-id-type="pmid">31125612</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lam B, Stromp TA, Hui Z, Vandsburger M. Myocardial native-T1 times are elevated as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis. Magn Reson Imaging. 2019;61:83&#x02013;9.<pub-id pub-id-type="pmid">31125612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Laohabut</surname><given-names>I</given-names></name><name><surname>Songsangjinda</surname><given-names>T</given-names></name><name><surname>Kaolawanich</surname><given-names>Y</given-names></name><name><surname>Yindeengam</surname><given-names>A</given-names></name><name><surname>Krittayaphong</surname><given-names>R</given-names></name></person-group><article-title>Myocardial extracellular volume fraction and T1 mapping by Cardiac magnetic resonance compared between patients with and without type 2 diabetes, and the Effect of ECV and T2D on Cardiovascular outcomes</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>771363</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.771363</pub-id><pub-id pub-id-type="pmid">34950715</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Laohabut I, Songsangjinda T, Kaolawanich Y, Yindeengam A, Krittayaphong R. Myocardial extracellular volume fraction and T1 mapping by Cardiac magnetic resonance compared between patients with and without type 2 diabetes, and the Effect of ECV and T2D on Cardiovascular outcomes. Front Cardiovasc Med. 2021;8:771363.<pub-id pub-id-type="pmid">34950715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Levelt</surname><given-names>E</given-names></name><name><surname>Mahmod</surname><given-names>M</given-names></name><name><surname>Piechnik</surname><given-names>SK</given-names></name><name><surname>Ariga</surname><given-names>R</given-names></name><name><surname>Francis</surname><given-names>JM</given-names></name><name><surname>Rodgers</surname><given-names>CT</given-names></name><etal/></person-group><article-title>Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes</article-title><source>Diabetes</source><year>2016</year><volume>65</volume><issue>1</issue><fpage>44</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.2337/db15-0627</pub-id><pub-id pub-id-type="pmid">26438611</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016;65(1):44&#x02013;52.<pub-id pub-id-type="pmid">26438611</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>YK</given-names></name><name><surname>Xia</surname><given-names>CC</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cardiac magnetic resonance T1 mapping for evaluating myocardial fibrosis in patients with type 2 diabetes mellitus: correlation with left ventricular longitudinal diastolic dysfunction</article-title><source>Eur Radiol</source><year>2022</year><volume>32</volume><issue>11</issue><fpage>7647</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s00330-022-08800-9</pub-id><pub-id pub-id-type="pmid">35567605</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Liu X, Gao Y, Guo YK, Xia CC, Shi R, Jiang L, et al. Cardiac magnetic resonance T1 mapping for evaluating myocardial fibrosis in patients with type 2 diabetes mellitus: correlation with left ventricular longitudinal diastolic dysfunction. Eur Radiol. 2022;32(11):7647&#x02013;56.<pub-id pub-id-type="pmid">35567605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>RV</given-names></name><name><surname>Abbasi</surname><given-names>SA</given-names></name><name><surname>Neilan</surname><given-names>TG</given-names></name><name><surname>Hulten</surname><given-names>E</given-names></name><name><surname>Coelho-Filho</surname><given-names>O</given-names></name><name><surname>Hoppin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Myocardial tissue remodeling in adolescent obesity</article-title><source>J Am Heart Assoc</source><year>2013</year><volume>2</volume><issue>4</issue><fpage>e000279</fpage><pub-id pub-id-type="doi">10.1161/JAHA.113.000279</pub-id><pub-id pub-id-type="pmid">23963758</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Shah RV, Abbasi SA, Neilan TG, Hulten E, Coelho-Filho O, Hoppin A, et al. Myocardial tissue remodeling in adolescent obesity. J Am Heart Assoc. 2013;2(4):e000279.<pub-id pub-id-type="pmid">23963758</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Storz</surname><given-names>C</given-names></name><name><surname>Hetterich</surname><given-names>H</given-names></name><name><surname>Lorbeer</surname><given-names>R</given-names></name><name><surname>Heber</surname><given-names>SD</given-names></name><name><surname>Schafnitzel</surname><given-names>A</given-names></name><name><surname>Patscheider</surname><given-names>H</given-names></name><etal/></person-group><article-title>Myocardial tissue characterization by contrast-enhanced cardiac magnetic resonance imaging in subjects with prediabetes, diabetes, and normal controls with preserved ejection fraction from the general population</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2018</year><volume>19</volume><issue>6</issue><fpage>701</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jex190</pub-id><pub-id pub-id-type="pmid">28950340</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Storz C, Hetterich H, Lorbeer R, Heber SD, Schafnitzel A, Patscheider H, et al. Myocardial tissue characterization by contrast-enhanced cardiac magnetic resonance imaging in subjects with prediabetes, diabetes, and normal controls with preserved ejection fraction from the general population. Eur Heart J Cardiovasc Imaging. 2018;19(6):701&#x02013;8.<pub-id pub-id-type="pmid">28950340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Swoboda</surname><given-names>PP</given-names></name><name><surname>McDiarmid</surname><given-names>AK</given-names></name><name><surname>Erhayiem</surname><given-names>B</given-names></name><name><surname>Ripley</surname><given-names>DP</given-names></name><name><surname>Dobson</surname><given-names>LE</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><etal/></person-group><article-title>Diabetes Mellitus, Microalbuminuria, and subclinical Cardiac Disease: identification and monitoring of individuals at risk of heart failure</article-title><source>J Am Heart Assoc</source><year>2017</year><volume>6</volume><issue>7</issue><fpage>e005539</fpage><pub-id pub-id-type="doi">10.1161/JAHA.117.005539</pub-id><pub-id pub-id-type="pmid">28716801</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Swoboda PP, McDiarmid AK, Erhayiem B, Ripley DP, Dobson LE, Garg P, et al. Diabetes Mellitus, Microalbuminuria, and subclinical Cardiac Disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc. 2017;6(7):e005539.<pub-id pub-id-type="pmid">28716801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TC</given-names></name><name><surname>Piehler</surname><given-names>KM</given-names></name><name><surname>Kang</surname><given-names>IA</given-names></name><name><surname>Kadakkal</surname><given-names>A</given-names></name><name><surname>Kellman</surname><given-names>P</given-names></name><name><surname>Schwartzman</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>10</issue><fpage>657</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht193</pub-id><pub-id pub-id-type="pmid">23756336</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35(10):657&#x02013;64.<pub-id pub-id-type="pmid">23756336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Treibel</surname><given-names>TA</given-names></name><name><surname>Fridman</surname><given-names>Y</given-names></name><name><surname>Bering</surname><given-names>P</given-names></name><name><surname>Sayeed</surname><given-names>A</given-names></name><name><surname>Maanja</surname><given-names>M</given-names></name><name><surname>Frojdh</surname><given-names>F</given-names></name><etal/></person-group><article-title>Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1</article-title><source>JACC Cardiovasc Imaging</source><year>2020</year><volume>13</volume><issue>1Part1</issue><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2019.03.017</pub-id><pub-id pub-id-type="pmid">31103587</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Treibel TA, Fridman Y, Bering P, Sayeed A, Maanja M, Frojdh F, et al. Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1. JACC Cardiovasc Imaging. 2020;13(1Part1):44&#x02013;54.<pub-id pub-id-type="pmid">31103587</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Schelbert</surname><given-names>EB</given-names></name><name><surname>Sabbah</surname><given-names>HN</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Gheorghiade</surname><given-names>M</given-names></name></person-group><article-title>Employing Extracellular volume Cardiovascular magnetic resonance measures of myocardial fibrosis to Foster Novel therapeutics</article-title><source>Circ Cardiovasc Imaging</source><year>2017</year><volume>10</volume><issue>6</issue><fpage>e005619</fpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.116.005619</pub-id><pub-id pub-id-type="pmid">28512159</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing Extracellular volume Cardiovascular magnetic resonance measures of myocardial fibrosis to Foster Novel therapeutics. Circ Cardiovasc Imaging. 2017;10(6):e005619.<pub-id pub-id-type="pmid">28512159</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x000e4;ni</surname><given-names>C</given-names></name><name><surname>Bi&#x000e8;re</surname><given-names>L</given-names></name><name><surname>Eichhorn</surname><given-names>C</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Aghayev</surname><given-names>A</given-names></name><etal/></person-group><article-title>Incremental value of extracellular volume assessment by cardiovascular magnetic resonance imaging in risk stratifying patients with suspected myocarditis</article-title><source>Int J Cardiovasc Imaging</source><year>2019</year><volume>35</volume><issue>6</issue><fpage>1067</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/s10554-019-01552-6</pub-id><pub-id pub-id-type="pmid">30756221</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Gr&#x000e4;ni C, Bi&#x000e8;re L, Eichhorn C, Kaneko K, Agarwal V, Aghayev A, et al. Incremental value of extracellular volume assessment by cardiovascular magnetic resonance imaging in risk stratifying patients with suspected myocarditis. Int J Cardiovasc Imaging. 2019;35(6):1067&#x02013;78.<pub-id pub-id-type="pmid">30756221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Hajdu</surname><given-names>M</given-names></name><name><surname>Knutsen</surname><given-names>MO</given-names></name><name><surname>V&#x000e9;rtes</surname><given-names>V</given-names></name><name><surname>Vorobcsuk-Varga</surname><given-names>N</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>G</given-names></name><name><surname>Wittmann</surname><given-names>I</given-names></name><etal/></person-group><article-title>Quality of glycemic control has significant impact on myocardial mechanics in type 1 diabetes mellitus</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>20180</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-24619-2</pub-id><pub-id pub-id-type="pmid">36424498</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hajdu M, Knutsen MO, V&#x000e9;rtes V, Vorobcsuk-Varga N, Moln&#x000e1;r G, Wittmann I, et al. Quality of glycemic control has significant impact on myocardial mechanics in type 1 diabetes mellitus. Sci Rep. 2022;12(1):20180.<pub-id pub-id-type="pmid">36424498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Neilan</surname><given-names>TG</given-names></name><name><surname>Mongeon</surname><given-names>FP</given-names></name><name><surname>Shah</surname><given-names>RV</given-names></name><name><surname>Coelho</surname><given-names>-Filho</given-names></name><name><surname>Otavio, Abbasi</surname><given-names>SA</given-names></name><name><surname>Dodson</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Myocardial extracellular volume expansion and the risk of recurrent Atrial Fibrillation after pulmonary vein isolation</article-title><source>JACC Cardiovasc Imaging</source><year>2014</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2013.08.013</pub-id><pub-id pub-id-type="pmid">24290570</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Neilan TG, Mongeon FP, Shah RV, Coelho -Filho, Otavio, Abbasi SA, Dodson JA, et al. Myocardial extracellular volume expansion and the risk of recurrent Atrial Fibrillation after pulmonary vein isolation. JACC Cardiovasc Imaging. 2014;7(1):1&#x02013;11.<pub-id pub-id-type="pmid">24290570</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>